Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,232	$ 7,571
Accounts receivable	556	0
Prepaid expenses	421	442
Other current assets	16	11
Total current assets	4,225	8,024
Other investment	5,350	5,350
Total assets	9,575	13,374
Current liabilities:
Accounts payable	390	1,198
Accrued research and development costs	52	90
Accrued expenses and other current liabilities	283	798
Total current liabilities	725	2,086
Commitments and contingencies (Note 8)	0	0
Stockholders' equity
Preferred stock, no par value, 100,000,000 shares authorized and 351,037 shares of Series A convertible preferred stock issued and outstanding at December 31, 2024 and 2023	0	0
Common stock, no par value, 400,000,000 shares authorized at December 31, 2024 and 2023; 2,710,096 and 2,645,096 shares issued at December 31, 2024 and 2023, respectively; 2,545,922 and 2,474,159 shares outstanding at December 31, 2024 and 2023, respectively	0	0
Paid-in capital	276,342	275,717
Accumulated deficit	(267,492)	(264,417)
Accumulated other comprehensive loss	0	(12)
Total stockholders' equity	8,850	11,288
Total liabilities and stockholders' equity	$ 9,575	$ 13,374